Search clinical trials for: MGCD0103

Total 20 results

Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Tumors

United States, Canada
Mirati Therapeutics Inc.

Terminated

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Myelodysplastic Syndromes | Myelogenous Leukemia, Acute

United States, Canada
Novartis

Completed

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Type 2 Diabetes Mellitus | Impaired Glucose Tolerance

United States, Canada, Finland, Australia, Germany, India, Italy
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

Canada, United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
Memorial Sloan Kettering Cancer Center
MethylGene Inc.

Completed

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Lisata Therapeutics, Inc.

Withdrawn

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Brain and Central Nervous System Tumors

United States
University Health Network, Toronto
AstraZeneca; Mirati Therapeutics Inc.

Withdrawn

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001)

Squamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth | Resectable Squamous Cell Carcinoma of Oral Cavity

Canada
Mirati Therapeutics Inc.

Terminated

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Completed

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Canada
Mirati Therapeutics Inc.

Terminated

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Advanced Cancer

United States
Mirati Therapeutics Inc.

Completed

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Myelodysplastic Syndrome

United States
Mirati Therapeutics Inc.

Completed

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Urothelial Carcinoma

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Non Hodgkin's Lymphoma | Tumors

Canada, United States
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Jonsson Comprehensive Cancer Center
Mirati Therapeutics Inc.; Phase One Foundation

Recruiting

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Rhabdomyosarcoma

United States

3

Subscribe